Please assess the completion status of the following clinical trial:

Trial Title: Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adrenocortical carcinoma~  * Newly diagnosed disease within the past 3 weeks~ * Any disease stage allowed~* Lansky performance status 60-100% (for patients ≤ 16 years old)~* Karnofsky performance status 60-100% (for patients \> 16 years old)~* Absolute neutrophil count ≥ 750/mm\^3~* Platelet count ≥ 75,000/mm\^3~* Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR serum creatinine based on age as follows:~  * 0.4 mg/dL (1 month to \< 6 months)~ * 0.5 mg/dL (6 months to \< 1 year of age)~ * 0.6 mg/dL (1 to \< 2 years of age~ * 0.8 mg/dL (2 to \< 6 years of age)~ * 1.0 mg/dL (6 to \< 10 years of age)~ * 1.2 mg/dL (10 to \< 13 years of age)~ * 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to \< 16 years of age)~ * 1.7 mg/dL (male) or 1.4 mg/dL (female) (≥ 16 years of age)~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* AST or ALT \< 2.5 times ULN~* Shortening fraction ≥ 27% by echocardiogram OR ejection fraction ≥ 50% by radionuclide angiogram~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No previous chemotherapy for adrenocortical carcinoma

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Stratum I (surgery, observation) (Type: EXPERIMENTAL): Patients undergo primary tumor resection and retroperitoneal lymph node sampling followed by observation. Patients who have undergone prior surgery without nodal sampling undergo observation only.
- Stratum II (exploratory surgery, observation) (Type: EXPERIMENTAL): Patients undergo primary tumor resection and extended regional lymph node dissection followed by observation. Patients who have undergone prior surgery with simple resection of the primary tumor undergo exploratory surgery with extended regional lymph node dissection followed by observation.
- Stratum III (chemotherapy, surgery) (Type: EXPERIMENTAL): Patients receive combination chemotherapy with filgrastim (G-CSF) for up to 30 weeks (10 courses) followed by mitotane alone for an additional 2 months. Some patients undergo surgery after chemotherapy course 2 or 4. Some patients undergo additional surgery after finishing all chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).